drugset / Trial / NCT01407497
Safety and Immunogenicity Study of a DNA Priming and MVA Boosting Strategy of HIV Vaccine
Phase 1
Completed
25 enrolled
Instituto Nacional de Saúde, Mozambique
European and Developing Countries Clinical Trials Partnership (EDCTP) · collabSwedish Institute for Communicable Disease Control, Sweden · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
While antiretroviral drugs have shown great promise in reducing HIV replication and thus in reducing HIV/AIDS associated morbi-mortality and HIV transmission, the cost is substantial and side effects are a potentially limiting factor. Development of an effective safe-affordable vaccine is likely to be the best way to stop further virus spread. The study aims to determine safety and immunogenicity of the DNA-vaccine at a dose of 600µg and 1200µg delivered id in combination with MVA-CMDR boost im.
Timeline
- Start
- 2011-08
- Primary completion
- 2013-03
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | DNA HIVIS | Vaccine | 600 ug | Intravenous |
| Comparator | DNA HIVIS | Vaccine | 1200 ug | Intravenous |
| Comparator | MVA-CMDR | Vaccine | 108 unknown | Intramuscular |